Skip to main content
Contact Us
Subscribe
E-Edition
75°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Morphic Holding Inc
(NQ:
MORF
)
27.91
-0.06 (-0.23%)
Streaming Delayed Price
Updated: 12:19 PM EDT, Apr 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Morphic Holding Inc
< Previous
1
2
Next >
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024
April 25, 2024
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic Holding, Inc. (MORF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
April 02, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Morphic Holding, Inc. (MORF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
March 26, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Morphic Holding Inc. (NASDAQ: MORF) is a Stock Spotlight on 7/17
July 17, 2023
Via
Investor Brand Network
Morphic Holding Inc. (NASDAQ: MORF) is a Stock Spotlight on 6/5
June 05, 2023
Via
Investor Brand Network
MORF Investor Notice: Abraham, Fruchter & Twersky, LLP Investigating Claims on Behalf of Investors of Morphic Holding, Inc. (NASDAQ:MORF)
March 20, 2024
From
Abraham, Fruchter & Twersky, LLP
Via
GlobeNewswire
Morphic Appoints Dr. Simon Cooper as Chief Medical Officer
March 19, 2024
Experienced Clinical Development Leader with Deep Experience in Immunology and Inflammatory Diseases
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic to Participate in March Investor Conferences
March 05, 2024
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2023
February 22, 2024
From
Morphic Therapeutic
Via
GlobeNewswire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Morphic Holding, Inc. (MORF) on Behalf of Investors
January 11, 2024
From
Law Offices of Howard G. Smith
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Morphic Holding, Inc. (MORF) on Behalf of Investors
January 10, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Morphic Holding, Inc. (MORF) on Behalf of Investors
January 04, 2024
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Morphic to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Morphic Therapeutic
Via
GlobeNewswire
Robbins LLP Reminds MORF Investors that it is Investigating Morphic Holdings, Inc. on Behalf of Investors
December 01, 2023
From
Robbins LLP
Via
Business Wire
Morphic Holding, Inc. Reminder: Robbins LLP is Investigating MORF on Behalf of Investors
November 22, 2023
From
Robbins LLP
Via
Business Wire
Morphic to Present at November Investor Conferences
November 10, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023
November 03, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
NASDAQ: MORF Investor Notice: Investigation over Possible Securities Laws Violations by Morphic Holding, Inc.
November 01, 2023
San Diego, CA -- (SBWIRE) -- 11/01/2023 -- Morphic Holding, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Morphic Holding Investigation: Johnson Fistel Encourages Shareholders with Losses to Contact the Firm Regarding Investigation
October 21, 2023
From
Johnson Fistel, LLP
Via
Business Wire
Morphic Holding SHAREHOLDER ALERT: Johnson Fistel Encourages Morphic Holding Shareholders with Losses to Contact the Firm Regarding Investigation
October 14, 2023
From
Johnson Fistel, LLP
Via
Business Wire
Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set
October 09, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
MORF INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Morphic Holding, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
September 29, 2023
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
Morphic Holdings Announces CEO Dr. Praveen Tipirneni to Take Temporary Medical Leave of Absence
September 26, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic to Present Positive EMERALD-1 Phase 2a Data for MORF-057 in Patients with Moderate to Severe Ulcerative Colitis in Abstract for UEGW 2023
September 22, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic Announces Participation in 2023 Wells Fargo Healthcare Conference
August 29, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic to Present at the Canaccord Genuity 43rd Annual Growth Conference
August 09, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023
August 03, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic to Present at the Jefferies Global Healthcare Conference
June 06, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic to Present at 2023 RBC Capital Markets Global Healthcare Conference
May 12, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic Presents New Biomarker Data at DDW 2023 Supporting MORF-057 Program in Ulcerative Colitis
May 11, 2023
-Data demonstrate increases in circulating plasmablasts, consistent with the increased antibody activity expected with anti-inflammatory mechanism of A4B7 inhibition-
From
Morphic Therapeutic
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.